Sanofi (SNYNF)
| Market Cap | 111.71B -16.2% |
| Revenue (ttm) | 54.85B +5.5% |
| Net Income | 9.17B +40.5% |
| EPS | 7.52 +44.2% |
| Shares Out | n/a |
| PE Ratio | 12.18 |
| Forward PE | 9.39 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 100,792 |
| Average Volume | 73,425 |
| Open | 93.76 |
| Previous Close | 92.98 |
| Day's Range | 93.60 - 93.76 |
| 52-Week Range | 90.05 - 122.03 |
| Beta | 0.37 |
| RSI | 46.78 |
| Earnings Date | Jan 29, 2026 |
About Sanofi
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines protecting against diphtheria, tetanus, pertussis, polio, Hib, and hepatitis B; influenza, COVID-19 vaccine Nuvaxovid, booster, meningitis, and travel and endemic vaccines, that in... [Read more]
Financial Performance
In 2025, Sanofi's revenue was 46.72 billion, an increase of 5.49% compared to the previous year's 44.29 billion. Earnings were 7.81 billion, an increase of 40.52%.
Financial numbers in EUR Financial StatementsNews
Press release: Filing of the 2025 U.S. Form 20-F and French “Document d'Enregistrement Universel” containing the Annual Financial Report
Filing of the 2025 U.S. Form 20-F and French “Document d'Enregistrement Universel” containing the Annual Financial Report
Sanofi, Teva Report Positive Phase 2b Results For Duvakitug
(RTTNews) - Sanofi SA (SNY) and Teva Pharmaceutical Industries Ltd. (TEVA) reported on Tuesday, positive long-term extension data from the phase 2b RELIEVE UCCD study of duvakitug in ulcerative coliti...
Sanofi announces leadership evolution in Specialty Care Business Unit
CAMBRIDGE, Mass., Feb. 17, 2026 /PRNewswire/ -- Sanofi today announced the appointment of Manuela Buxo as Head of Specialty Care, effective March 1, 2026.
Teva, Sanofi's Phase 2b Trial Of Duvakitug Shows Durable Efficacy In UC & Crohn's
(RTTNews) - Teva Pharmaceutical Industries Ltd. (TEVA) and Sanofi (SNY) will hold an investor call and webcast today to highlight new Phase 2b maintenance data for Duvakitug. The investigational thera...
Teva Pharmaceutical's New Study Shows Lasting Relief For Inflammatory Bowel Disease Patients
Teva Pharmaceutical Industries Limited (NYSE: TEVA) shares are higher during Tuesday’s premarket session as the company is discussing positive results from its recent clinical study. Positive Data Fr...
Teva (TEVA) and Sanofi Report Positive Results for Duvakitug in UC and Crohn's
Teva (TEVA) and Sanofi Report Positive Results for Duvakitug in UC and Crohn's
Teva, Sanofi report durable phase 2b efficacy for duvakitug in ulcerative colitis, Crohn’s disease
Teva and Sanofi's duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn's disease
In the RELIEVE UCCD LTE phase 2b study, duvakitug showed robust, durable efficacy for an additional 44 weeks in UC and CD patients who had responded after 14 weeks of induction Duvakitug was well tole...
Press Release: Sanofi and Teva's duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn's disease
Sanofi and Teva's duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn's disease In the RELIEVE UCCD LTE phase 2b study, duvakitug sh...
Press Release: Sanofi and Teva's duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn's disease
Sanofi and Teva's duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn's disease
Sanofi (SNY) Study Shows Significant Reduction in Infant RSV Hospitalizations
Sanofi (SNY) Study Shows Significant Reduction in Infant RSV Hospitalizations
Sanofi’s Beyfortus shows hospitalization benefit across two RSV seasons
Sanofi expands Hyd GCC, to host around 5k workers
Hyderabad: In a move that bolsters Hyderabad's rapidly growing stature as a pharma global capability centre, Sanofi Healthcare India has expanded its .
Drugmaker Sanofi to expand India GCC, increase workforce to over 4,500 employees
French drugmaker Sanofi said on Monday it will expand its global capability centre (GCC) in the southern Indian city of Hyderabad, and increase its workforce to more than 4,500 employees.
Sanofi: Beyfortus Study Shows Benefit For Infants Beyond First RSV Season
(RTTNews) - Sanofi (SNY) said a universal respiratory syncytial virus immunization program using Beyfortus or nirsevimab was associated with a statistically significant reduction in RSV-related hospit...
Press Release: Beyfortus study published in The Lancet Infectious Diseases shows benefit for infants beyond first RSV season
Beyfortus study published in The Lancet Infectious Diseases shows benefit for infants beyond first RSV season First study showing that infants immunized against RSV in their first season had fewer RSV...
Sanofi (SNY) Appoints New CEO Amidst Stock Challenges
Sanofi (SNY) Appoints New CEO Amidst Stock Challenges
Sanofi Stock Near 52-Week Low As Leadership Shakeup Rattles Investors
Sanofi SA (NASDAQ: SNY) shares are down during Friday’s premarket session as the company faces leadership changes amid ongoing challenges in its drug pipeline. On Thursday, the French drugmaker with ...
Sanofi Stock Near 52-Week Low As Leadership Shakeup Rattles Investors
Sanofi SA (NASDAQ: SNY) shares are down during Friday's premarket session as the company faces leadership changes amid ongoing challenges in its drug pipeline.
Sanofi's new CEO needs to fix drug pipeline and navigate Trump
Sanofi's incoming CEO, 65-year-old Belén Garijo, faces a major task to win over investors, accelerate the French company's stalled drug development pipeline and navigate vaccine scepticism in the Unit...
French vaccine maker Sanofi ousts CEO Paul Hudson with Merck boss to take over
French drugmaker Sanofi ousted CEO Paul Hudson on Thursday, ending a six-year tenure marked by a stalled drive to replace blockbuster drugs going off patent and rising pressure from US anti-vaccine po...
Sanofi: CEO Leaves With Project Rejuvenation Unfinished, But Stock Undervalued
Sanofi SA (SNY) Stock Price Down 3.43% on Feb 12
Sanofi SA (SNY) Stock Price Down 3.43% on Feb 12
Sanofi Tumbles After Board Shockingly Ousts CEO Paul Hudson
Sanofi stock skidded Thursday after the pharma giant's board ousted Paul Hudson as CEO, replacing him with Merck KGaA's Belen Garijo.